Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial

Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection A Phase 2 Dose-Ranging Randomized Clinical Trial

Importance The monoclonal antibody combination of casirivimab and imdevimab reduced viral load, hospitalization, or death when administered as a 1200-mg or greater intravenous (IV) dose in a phase 3 COVID-19 outpatient study. Subcutaneous (SC) and/or lower IV doses should increase accessibility and/...

Full description

Saved in:
Bibliographic Details
Published in:JAMA network open Vol. 5; no. 8; p. e2225411
Main Authors: Portal-Celhay, Cynthia, Forleo-Neto, Eduardo, Eagan, Will, Musser, Bret J., Davis, John D., Turner, Kenneth C., Norton, Thomas, Hooper, Andrea T., Hamilton, Jennifer D., Pan, Cynthia, Mahmood, Adnan, Baum, Alina, Kyratsous, Christos A., Kim, Yunji, Parrino, Janie, Kampman, Wendy, Roque-Guerrero, Lilia, Stoici, Roxana, Fatakia, Adil, Soo, Yuhwen, Geba, Gregory P., Kowal, Bari, DiCioccio, A. Thomas, Stahl, Neil, Lipsich, Leah, Braunstein, Ned, Herman, Gary A., Yancopoulos, George D., Weinreich, David M., Altamirano, Dario, Ellington, Dickson, Karimjee, Najmuddin, Daudjee, Munib, Laabs, Jessica, Marler, Karen, Calais, Natalee, Sheppard, Zachary, Carroll, Kristy, Kohli, Anita, McIntyre, Vicki, Sachdeva, Yessica, Carney, Ashley, McFarland, Amanda, Gibson, Dina, Ekoko, Victorine, Kim, Kenneth, Ahn, Jason, Paryani, Nayna, Mottola, Amber, Day, Eva, Navarro, Martha, Vutikullird, Apinya, Gomez Ramirez, Ana, Capote, Javier, Paz, Gisel, Patel, Nancy, Patel, Ravikumar, Sattar, Ryan, Seep, Michael, Brown, Celeste, Whatley, Joshua, Levinson, Dennis, Ahmed, Azazuddin, James, Norman, Alvi, Saad, Kuehl, Ann, Koilpillai, Robinson, Cassady, Stephanie, Cox, Jennifer, Torres, Eduardo, Winnie, Michael, Verma, Omesh, Leggett, Richard, Reyes, Ramon, Beck, Keith, Poliquin, Brian, Mussaji, Murtaza, Shah, Jignesh, Eppensteiner, John, Limkakeng, Alexander, Francis, Samuel, Boghara, Haresh, Patel, Sunny, Eichelbaum, Bari, Anderson, Duane, Su, Sean, Akhavan, Alexander, Venglik, Joy, Kirby, Diana, Fedora, Crista, Fakih, Faisal A., Fakih, Faisal M., Alvarado, Fernando, Layish, Daniel, Diaz, Jose, Perez, Andres, Patel, Bhaktasharan, Tarshis, Gary
Format: Journal Article
Language:English
Published: Chicago American Medical Association 15-08-2022
Subjects:
Asymptomatic
Clinical trials
Coronaviruses
COVID-19
Drug dosages
Hispanic Americans
Infectious Diseases
Monoclonal antibodies
Online Only
Original Investigation
Severe acute respiratory syndrome coronavirus 2
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Importance The monoclonal antibody combination of casirivimab and imdevimab reduced viral load, hospitalization, or death when administered as a 1200-mg or greater intravenous (IV) dose in a phase 3 COVID-19 outpatient study. Subcutaneous (SC) and/or lower IV doses should increase accessibility and/or drug supplies for patients. Objective To assess the virologic efficacy of casirivimab and imdevimab across different IV and SC doses compared with placebo. Design, Setting, and Participants This phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study included outpatients with SARS-CoV-2 infection at 47 sites across the United States. Participants could be symptomatic or asymptomatic; symptomatic patients with risk factors for severe COVID-19 were excluded. Data were collected from December 15, 2020, to March 4, 2021. Interventions Patients were randomized to a single IV dose (523 patients) of casirivimab and imdevimab at 300, 600, 1200, or 2400 mg or placebo; or a single SC dose (292 patients) of casirivimab and imdevimab at 600 or 1200 mg or placebo. Main Outcomes and Measures The primary end point was the time-weighted average daily change from baseline (TWACB) in viral load from day 1 (baseline) through day 7 in patients seronegative for SARS-CoV-2 at baseline. Results Among 815 randomized participants, 507 (282 randomized to IV treatment, 148 randomized to SC treatment, and 77 randomized to placebo) were seronegative at baseline and included in the primary efficacy analysis. Participants randomized to IV had a mean (SD) age of 34.6 (9.6) years (160 [44.6%] men; 14 [3.9%] Black; 121 [33.7%] Hispanic or Latino; 309 [86.1%] White); those randomized to SC had a mean age of 34.1 (10.0) years (102 [45.3%] men; 75 [34.7%] Hispanic or Latino; 6 [2.7%] Black; 190 [84.4%] White). All casirivimab and imdevimab treatments showed significant virologic reduction through day 7. Least-squares mean differences in TWACB viral load for casirivimab and imdevimab vs placebo ranged from –0.56 (95% CI; –0.89 to –0.24) log10copies/mL for the 1200-mg IV dose to –0.71 (95% CI, –1.05 to –0.38) log10copies/mL for the 2400-mg IV dose. There were no adverse safety signals or dose-related safety findings, grade 2 or greater infusion-related or hypersensitivity reactions, grade 3 or greater injection-site reactions, or fatalities. Two serious adverse events not related to COVID-19 or the study drug were reported. Conclusions and Relevance In this randomized clinical trial including outpatients with asymptomatic and low-risk symptomatic SARS-CoV-2, all IV and SC doses of casirivimab and imdevimab comparably reduced viral load. Trial Registration ClinicalTrials.gov Identifier:NCT04666441
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-News-3
content type line 23
ISSN:2574-3805
2574-3805
DOI:10.1001/jamanetworkopen.2022.25411